Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹158 Cr
Revenue (TTM)
₹89 Cr
Net Profit (TTM)
₹22 Cr
ROE
-12.2 %
ROCE
-10 %
P/E Ratio
7.3
P/B Ratio
1.4
Industry P/E
26.59
EV/EBITDA
17.6
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹39.4
EPS
₹7.3
Face value
10
Shares outstanding
29,457,248
CFO
₹-57.58 Cr
EBITDA
₹-40.83 Cr
Net Profit
₹-139.99 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Brooks Lab
| -33.4 | -20.5 | -31.2 | -51.8 | -4.7 | -2.2 | -2.9 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Brooks Lab
| -56.4 | 23.4 | 32.6 | 8.9 | 43.9 | 170.4 | -51.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Brooks Lab
|
53.4 | 158.2 | 88.9 | 6.5 | 7.2 | 20.2 | 7.3 | 1.4 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,499.2 | 9,167.3 | 1,196.4 | 149.4 | -- | 27.5 | 61.3 | 13.1 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. The company offers tablets, dry syrup, general injections, liquid injections, dry powder injections, eye/ear drops, nasal drops, oncology products,... hormonal injections, etc. It also exports its products in Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India. Read more
Incorporated
2002
Chairman
--
Managing Director
--
Headquarters
Solan Dist, Himachal Pradesh
Website
Looking for more details about Brooks Laboratories Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
The share price of Brooks Laboratories Ltd is ₹53.38 (NSE) and ₹53.69 (BSE) as of 02-Apr-2026 IST. Brooks Laboratories Ltd has given a return of -4.74% in the last 3 years.
The P/E ratio of Brooks Laboratories Ltd is 7.32 times as on 02-Apr-2026, a 72 discount to its peers’ median range of 26.59 times.
The P/B ratio of Brooks Laboratories Ltd is 1.36 times as on 02-Apr-2026, a 70 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
3.24
|
|
2024
|
0.00
|
3.71
|
|
2023
|
0.00
|
2.09
|
|
2022
|
0.00
|
2.05
|
|
2021
|
0.00
|
1.94
|
The 52-week high and low of Brooks Laboratories Ltd are Rs 164.02 and Rs 36.30 as of 04-Apr-2026.
Brooks Laboratories Ltd has a market capitalisation of ₹ 158 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Brooks Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.